209 related articles for article (PubMed ID: 37321815)
1. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial.
Verweij ME; Tanaka MD; Kensen CM; van der Heide UA; Marijnen CAM; Janssen T; Vijlbrief T; van Grevenstein WMU; Moons LMG; Koopman M; Lacle MM; Braat MNGJA; Chalabi M; Maas M; Huibregtse IL; Snaebjornsson P; Grotenhuis BA; Fijneman R; Consten E; Pronk A; Smits AB; Heikens JT; Eijkelenkamp H; Elias SG; Verkooijen HM; Schoenmakers MMC; Meijer GJ; Intven M; Peters FP
BMJ Open; 2023 Jun; 13(6):e065010. PubMed ID: 37321815
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
Zhang MX; Li XB; Guan BJ; Guan GX; Lin XY; Wu XD; Chi P; Xu BH
BMJ Open; 2019 Mar; 9(3):e025944. PubMed ID: 30904869
[TBL] [Abstract][Full Text] [Related]
3. Optimisation of Organ Preservation treatment strategies in patients with rectal cancer with a good clinical response after neoadjuvant (chemo)radiotherapy: Additional contact X-ray brachytherapy versus eXtending the observation period and local excision (OPAXX) - protocol for two multicentre, parallel, single-arm, phase II studies.
Geubels BM; van Triest B; Peters FP; Maas M; Beets GL; Marijnen CAM; Custers PA; Rutten HJT; Theuws JCM; Verrijssen AE; Cnossen JS; Burger JWA; Grotenhuis BA
BMJ Open; 2023 Dec; 13(12):e076866. PubMed ID: 38159950
[TBL] [Abstract][Full Text] [Related]
4. Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches.
Bach SP;
Colorectal Dis; 2022 May; 24(5):639-651. PubMed ID: 35114057
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750).
Sun Myint A; Rao C; Barbet N; Thamphya B; Pace-Loscos T; Schiappa R; Magné N; Martel-Lafay I; Mineur L; Deberne M; Zilli T; Dhadda A; Gerard JP
Colorectal Dis; 2023 Nov; 25(11):2160-2169. PubMed ID: 37837240
[TBL] [Abstract][Full Text] [Related]
6. A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.
Hudson EM; Noutch S; Brown S; Adapala R; Bach SP; Burnett C; Burrage A; Gilbert A; Hawkins M; Howard D; Jefford M; Kochhar R; Saunders M; Seligmann J; Smith A; Teo M; Webb EJ; Webster A; West N; Sebag-Montefiore D; Gollins S; Appelt AL
BMJ Open; 2022 Apr; 12(4):e049119. PubMed ID: 35487526
[TBL] [Abstract][Full Text] [Related]
7. RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial.
Burbach JP; Verkooijen HM; Intven M; Kleijnen JP; Bosman ME; Raaymakers BW; van Grevenstein WM; Koopman M; Seravalli E; van Asselen B; Reerink O
Trials; 2015 Feb; 16():58. PubMed ID: 25888548
[TBL] [Abstract][Full Text] [Related]
8. Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in low-lying early rectal cancer: study protocol for a single-arm, multicentre, prospective, phase II trial (TORCH-E).
Chen Y; Wang Y; Zhang H; Wan J; Shen L; Wang Y; Zhou M; Wu R; Yang W; Zhou S; Cai S; Li X; Zhang Z; Xia F
BMJ Open; 2023 Oct; 13(10):e076048. PubMed ID: 37802608
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.
Gerard JP; Barbet N; Schiappa R; Magné N; Martel I; Mineur L; Deberne M; Zilli T; Dhadda A; Myint AS;
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):356-367. PubMed ID: 36801007
[TBL] [Abstract][Full Text] [Related]
10. Quality-of-life outcomes in older patients with early-stage rectal cancer receiving organ-preserving treatment with hypofractionated short-course radiotherapy followed by transanal endoscopic microsurgery (TREC): non-randomised registry of patients unsuitable for total mesorectal excision.
Gilbert A; Homer V; Brock K; Korsgen S; Geh I; Hill J; Gill T; Hainsworth P; Tutton M; Khan J; Robinson J; Steward M; Cunningham C; Kaur M; Magill L; Russell A; Quirke P; West NP; Sebag-Montefiore D; Bach SP;
Lancet Healthy Longev; 2022 Dec; 3(12):e825-e838. PubMed ID: 36403589
[TBL] [Abstract][Full Text] [Related]
11. STAR-TREC: An International Three-arm Multicentre, Partially Randomised Controlled Trial Incorporating an External Pilot.
Bach SP
Clin Oncol (R Coll Radiol); 2023 Feb; 35(2):e107-e109. PubMed ID: 36577551
[TBL] [Abstract][Full Text] [Related]
12. Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma.
Abraha I; Aristei C; Palumbo I; Lupattelli M; Trastulli S; Cirocchi R; De Florio R; Valentini V
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD002102. PubMed ID: 30284239
[TBL] [Abstract][Full Text] [Related]
13. Patient- and physician-reported radiation-induced toxicity of short-course radiotherapy with a prolonged interval to surgery for rectal cancer.
Verweij ME; Hoendervangers S; von Hebel CM; Pronk A; Schiphorst AHW; Consten ECJ; Smits AB; Heikens JT; Verdaasdonk EGG; Rozema T; Verkooijen HM; van Grevenstein WMU; Intven MPW
Colorectal Dis; 2023 Jan; 25(1):24-30. PubMed ID: 36054676
[TBL] [Abstract][Full Text] [Related]
14. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
[TBL] [Abstract][Full Text] [Related]
15. Online MR guided dose escalated radiotherapy for organ preservation in distal rectal cancer.
Boeke S; Uder L; Ehlers J; Butzer S; Baumeister S; Boldt J; Nachbar M; Lo Russo M; Mönnich D; Nikolaou K; Zips D; Thorwarth D; Gani C
Clin Transl Radiat Oncol; 2022 Nov; 37():153-156. PubMed ID: 36339638
[TBL] [Abstract][Full Text] [Related]
16. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society.
Siegel R; Burock S; Wernecke KD; Kretzschmar A; Dietel M; Loy V; Koswig S; Budach V; Schlag PM
BMC Cancer; 2009 Feb; 9():50. PubMed ID: 19200365
[TBL] [Abstract][Full Text] [Related]
17. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
18. Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance.
Hafeez S; Webster A; Hansen VN; McNair HA; Warren-Oseni K; Patel E; Choudhury A; Creswell J; Foroudi F; Henry A; Kron T; McLaren DB; Mitra AV; Mostafid H; Saunders D; Miles E; Griffin C; Lewis R; Hall E; Huddart R
BMJ Open; 2020 Dec; 10(12):e041005. PubMed ID: 33384390
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of hypofractionated adaptive radiotherapy using the MR Linac in localised pancreatic cancer: protocol summary of the Emerald-Pancreas phase 1/expansion study located at Oxford University Hospital, UK.
Teoh S; Ooms A; George B; Owens R; Chu KY; Drabble J; Robinson M; Parkes MJ; Swan L; Griffiths L; Nugent K; Good J; Maughan T; Mukherjee S
BMJ Open; 2023 Sep; 13(9):e068906. PubMed ID: 37709321
[TBL] [Abstract][Full Text] [Related]
20. A novel approach for radiotherapy dose escalation in rectal cancer using online MR-guidance and rectal ultrasound gel filling - Rationale and first in human.
Gani C; Lo Russo M; Boeke S; Wegener D; Gatidis S; Butzer S; Boldt J; Mönnich D; Thorwarth D; Nikolaou K; Zips D; Nachbar M
Radiother Oncol; 2021 Nov; 164():37-42. PubMed ID: 34534612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
